# Andrew Tutt

Source: https://onco.cc/people/andrew-tutt/  
OnCo record `andrew-tutt` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Led OlympiA, the trial that showed a year of olaparib after surgery improves survival in BRCA-mutated breast cancer.

## Summary

Andrew Tutt is Director of the Breast Cancer Now Toby Robins Research Centre at The Institute of Cancer Research and a consultant clinical oncologist at The Royal Marsden and Guy's. His specialisms are triple-negative breast cancer, BRCA and DNA repair, PARP inhibitors and platinum chemotherapy. His work on BRCA-deficient breast cancer runs from the first clinical proof-of-concept for a PARP inhibitor, through the TNT trial of carboplatin in BRCA1/2-mutated and triple-negative subgroups reported in Nature Medicine, to OlympiA, the adjuvant olaparib trial in BRCA-mutated breast cancer published in the New England Journal of Medicine. This body of work defined DNA-repair-targeted therapy in breast cancer. His ICR profile and PubMed listing are linked.

## Fields

- Kind: Person
- Last checked: 2026-09-08
- Role: Director, Breast Cancer Now Toby Robins Research Centre, ICR; Consultant Clinical Oncologist, Royal Marsden and Guy's
- Specialisms: Triple-negative breast cancer; BRCA and DNA repair; PARP inhibitors; Platinum chemotherapy

## Sources

- ICR profile: https://www.icr.ac.uk/research-and-discoveries/our-research/researchers/professor-andrew-tutt
- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Tutt%20A%5BAuthor%5D%20olaparib%20breast

## Connected records

- cancers: [Triple-negative breast cancer (TNBC)](https://onco.cc/cancers/tnbc/)
- technologies: [PARP inhibitors](https://onco.cc/technologies/parp-inhibitor/), [Platinum agents](https://onco.cc/technologies/platinum/)
- targets: [BRCA1 / BRCA2 (HRD)](https://onco.cc/targets/brca/), [PARP](https://onco.cc/targets/parp/)
- drugs: [Carboplatin](https://onco.cc/drugs/carboplatin/), [Olaparib](https://onco.cc/drugs/olaparib/)
- institutions: [Breast Cancer Now](https://onco.cc/institutions/breast-cancer-now/), [Guy's and St Thomas' NHS Foundation Trust / King's Health Partners Cancer Centre](https://onco.cc/institutions/guys-st-thomas/), [The Institute of Cancer Research](https://onco.cc/institutions/icr-london/), [The Royal Marsden](https://onco.cc/institutions/royal-marsden/)
- trials: [OlympiA](https://onco.cc/trials/olympia/), [TNT (Triple Negative Trial)](https://onco.cc/trials/tnt/)
- key papers: [Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial](https://onco.cc/key-papers/paper-tutt-nat-med/), [OlympiA: a year of olaparib after surgery for BRCA-mutated, high-risk early breast cancer](https://onco.cc/key-papers/paper-olympia-nejm-2021/), [Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer](https://onco.cc/key-papers/paper-olympia-overall-survival-ann-oncol-2022/), [Sustained benefit of adjuvant olaparib in women with germline BRCA1- and BRCA2-associated high-risk HER2-negative early breast cancer: updated results from the OlympiA phase III trial](https://onco.cc/key-papers/paper-olympia-6-year-update-ann-oncol-2026/)
- roadmaps: [Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem](https://onco.cc/roadmaps/tnbc-roadmap/)
- people: [Jean Abraham](https://onco.cc/people/jean-abraham/)

---
JSON: https://onco.cc/api/v1/entities/andrew-tutt.json